ARTICLE | Company News
InNexus, Xeris Pharmaceuticals Inc. deal
December 21, 2009 8:00 AM UTC
The companies will use Xeris' formulation injection technology to develop InNexus' antibodies for subcutaneous injection. The antibodies include DXL702r, preclinical antibody against EGFR 2 ( HER2; ...